Funding Opportunity RFA-FD-18-020 from the NIH Guide for Grants and Contracts. FDA's CDER is seeking a computational modeling approach to study the effects of mucociliary clearance on localized drug absorption in the nasal cavity. The modeling approach would utilize computational fluid dynamics (CFD) simulations of inhalation and droplet/particle transport to provide regional nasal spray deposition data, while the three-dimensional mucociliary clearance model would demonstrate localized drug absorption and indicate the efficacy of drug products that target specific nasal regions. The model should be adaptable to cases of interindividual variability, which may include variations in mucociliary clearance rates, changes in nasal geometry, and the presence of relevant disease states (e.g., nasal inflammation, changes in mucus properties, etc.).

Funding Opportunity RFA-FD-18-019 from the NIH Guide for Grants and Contracts. The purpose of this project is to incorporate drug product quality attributes into dermal physiologically-based pharmacokinetic models developed for dermatological topical dosage forms and transdermal delivery systems. The developed models will be utilized to identify drug-product specific critical quality attributes (model qualification) and perform virtual bioequivalence assessments between brand name and generic drug products to inform regulatory decisions relating to the development of dermatological drug products.

Notice NOT-HL-18-609 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-715 from the NIH Guide for Grants and Contracts. This FOA invites existing Alzheimer's Disease Patient Registry cooperative agreements that are described in Part 2, Section I to submit revision and or renewal applications. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application.

Notice NOT-NS-18-041 from the NIH Guide for Grants and Contracts

Performs mass spectrometry experiments and subsequent data analysis. Knowledge and experience in genomics, immunotherapy, bioinformatics and the related...
From Indeed - Tue, 20 Mar 2018 21:11:36 GMT - View all Seattle, WA jobs

Bachelor’s degree in Biology, Engineering, Computer Science or Bioinformatics. Under the direction of the Medical Informatics Director, the Bioinformatics...
From Versiti - Tue, 20 Mar 2018 21:11:20 GMT - View all Milwaukee, WI jobs

Bachelor’s degree in Biology, Engineering, Computer Science or Bioinformatics. Under the direction of the Medical Informatics Director, the Bioinformatics...
From BloodCenter of Wisconsin - Tue, 20 Mar 2018 21:11:20 GMT - View all Milwaukee, WI jobs

CuraCloud is developing a new generation of AI-enabled diagnostic services for health systems and cancer researchers, with a focus on medical image analysis and...
From Indeed - Tue, 20 Mar 2018 19:19:58 GMT - View all Seattle, WA jobs

Our scientists will be responsible for the development of bioinformatics analysis workflow, biomarker signatures as well as clinical diagnostic assays....
From Indeed - Tue, 20 Mar 2018 19:19:11 GMT - View all Seattle, WA jobs

Emphasis in Computer science, Data Science, Statistics, Physics, Computational Biology or Bioinformatics strongly preferred....
From Microsoft - Tue, 20 Mar 2018 17:01:42 GMT - View all Redmond, WA jobs

Over the past several years, R has enjoyed tremendous growth in usage & mindshare in the data science community, reaching a user count in the millions....
From Microsoft - Tue, 20 Mar 2018 16:59:29 GMT - View all Redmond, WA jobs

Funding Opportunity RFA-DA-19-004 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to fund a single interdisciplinary Coordinating Center to formalize and centralize support of the rural opioid initiative administered by NIDA and co-funded by CDC, SAMHSA, and ARC. This initiative was funded under RFA-DA-17-014 and RFA-DA-17-023 The Coordinating Center will provide scientific, technical, regulatory, ethical, and logistical support of data comparability, new data collection, and data integration; developing integrated rural opioid initiative datasets; assisting grantees with acquisition and analysis of local administrative and/or research datasets that enable evaluation of their implementation activities or augment their community assessments; conducting requested analyses that relate to the integrated rural opioid initiative datasets; developing and executing a rural opioid initiative publication and dissemination plan; and providing logistical support for in-person meetings, conference calls, and webinars that include the rural opioid initiative grantees and funders. The Coordinating Center will be represented on the rural opioid initiative executive steering committee, along with the funders and rural opioid initiative grantees.

Notice NOT-AG-18-007 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-18-017 from the NIH Guide for Grants and Contracts. The purpose of this project is to identify skin physiology characteristics that differ between healthy and skin disease population groups and incorporate them into dermal physiologically-based pharmacokinetic models to improve their predictability. The models developed will be utilized to perform virtual bioequivalence assessments between brand name and generic drug products to inform regulatory decisions relating to the development of generic topical dermatological drug products and transdermal delivery systems.

Notice NOT-AG-18-005 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Bioinformatician Opportunities - Boston, Massachusetts Paramount Recruitment - Clinical Bioinformatics - Cancer Genomics - NGS - Computational Biology, Big Data - Epigenomics - Data Science - Multi Omics - Statistics - Machine Learning - Programming Her Boston, Massachusetts

Notice NOT-EB-18-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-18-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support the research necessary to elucidate how systematic alterations to the qualitative (Q1) and/or quantitative (Q2) composition of topical formulations impacts their physical, structural, and functional properties. A key aspect of the research relates to understanding how the thermodynamic properties of a topical dosage form change as it undergoes metamorphosis during dose application and drying on the skin, how the drug's thermodynamic activity profile during the metamorphosis of the dosage form may compare between compositionally different (non-Q1 and/or non-Q2) topical formulations, and how these and other forces may modulate the rate and extent to which topically applied drugs may become available at or near their site(s) of action in the skin. Another key aspect of the research relates to identifying and understanding other potential failure modes for bioequivalence (BE) and/or therapeutic equivalence (TE) (e.g., differences in irritation potential) that may arise between compositionally different (non-Q1 and/or non-Q2) topical formulations.

Notice NOT-CA-18-057 from the NIH Guide for Grants and Contracts